Curriculum
CURRENT POSITION Full Professor, scientific-disciplinary sector MEDS 22/A (formerly MED36) Diagnostic Imaging and Radiotherapy. Affiliation with the Department of Translational Medicine and for Romagna, University of Ferrara.
ACADEMIC QUALIFICATIONS
1982: Degree in Medicine and Surgery, University of Pisa
1985: Diploma of Specialization in Nuclear Medicine, University of Pisa
1990: Diploma of Specialization in Radiodiagnostics, University of Ferrara
1997: Diploma of Specialization in Cardiology, University of Ferrara
TEACHING ACTIVITIES
Lecturer in Diagnostic Imaging and Radiation Protection in the following Degree Programs at UNIFE:
Medicine and Surgery
Dentistry and Dental Prosthetics
Radiology Medical Technicians
Health Professions in Diagnostic Techniques.
MANAGERIAL ACTIVITIES
Currently Director of the Department of Radiology and Laboratory Medicine of the University Hospital S. Anna in Ferrara, and the University Radiology Unit of the same Hospital.
Responsible for the University’s Radiation Protection Medical Surveillance.
Previous Positions held at the University of Ferrara:
Dean of the Faculty of Medicine, Pharmacy, and Prevention
President of the University Ethics Committee
Coordinator of the Study Program in Health Techniques in Radiology and Radiotherapy
Coordinator of the Study Program in Health Professions in Diagnostic Techniques
Director of the School of Specialization in Radiodiagnostics
Director of the School of Specialization in Nuclear Medicine
Director of the 2nd Level Master’s Program in "Science and Technology of Radiopharmaceuticals"
RESEARCH ACTIVITIES Pre-clinical research in the field of radiopharmacy aimed at designing, synthesizing, and biologically evaluating new radiopharmaceuticals for diagnostic imaging (Tc-99m) and radiometabolic therapy (Re-188).
Collaborations include:
CIS bio international (Gif-sur-Yvette, France) and the French Atomic Energy Commission (CEA): Designing in vitro and in vivo biological activity evaluation studies. This research led to the discovery of a new diagnostic agent for myocardial perfusion imaging (99mTcN-NOET).
Nihon Medi-Physics (Tokyo, Japan): Evaluating the structure-activity relationship of new diagnostic tracers with selective myocardial cell affinity. One of these compounds (99mTcN-DBODC) underwent preliminary clinical evaluation.
Schering AG (Berlin, Germany): Development of an innovative method for synthesizing new radiotherapeutic agents containing the β-emitting radionuclide rhenium-188. The product 188ReN-Lipiodol was tested clinically for hepatocellular carcinoma treatment in collaboration with Fremantle Hospital, University of Western Australia.
Development of innovative automatic synthesis modules for beta-emitting radionuclides in collaboration with industry.
Department of Physics, University of Ferrara: Development of a "YAP(S)PET" scanner, which combines CT-SPECT and CT-PET imaging for small animal research.
Collaboration with the International Atomic Energy Agency (IAEA) on Coordinated Research Projects related to Tc-99m radiopharmaceuticals for sentinel node detection and cancer diagnosis, and development of Re-188 and Y-90-based radiopharmaceuticals for radionuclide therapy.
Collaboration with INFN (National Institute of Nuclear Physics) for new methodologies for Tc-99m production via cyclotron.
Director of the section managing the "Nuclear Medicine and Molecular Imaging Laboratory" excellence center for radiochemistry under the Italian Association of Nuclear Medicine (AIMN).
Clinical research focused on nuclear medicine, specifically:
Cardiology: In collaboration with the Nuclear Medicine Unit of the University Hospital of Ferrara, evaluation of the biodistribution, dosimetry, and safety profile of the new radiopharmaceutical 99mTc-N-DBODC for myocardial perfusion imaging.
Oncology: In collaboration with Dr. R. Galeotti from the Radiology Department, preliminary assessment of the toxicity and therapeutic efficacy of 188ReN-Lipiodol for hepatocellular carcinoma treatment, administered through intra-arterial or superselective hepatic artery injection.
Radiology: Research on the appropriateness of diagnostic imaging, a crucial topic for scientific societies, HTA organizations, and clinical government authorities, focusing on the optimization of resources, cost reduction, and minimizing biological risks for patients.
CLINICAL ACTIVITIES Professor Giganti’s clinical activities currently take place at the University Radiology Unit of the S. Anna University Hospital of Ferrara, where he is responsible for the organizational and managerial aspects of the complex structure, as well as performing and reporting on around 200 exams weekly in traditional radiology (thoracic radiology) and MRI (abdomen and pelvis). Until December 2011, his clinical activity was carried out at the Nuclear Medicine Unit of the University Hospital of Ferrara. This hospital unit has a traditional gamma camera, a gamma camera with a dedicated CT scanner for attenuation correction, and mobile units for PET-CT exams. Additionally, radiometabolic therapies for hyperthyroidism and bone pain treatment using beta-emitting radionuclides were performed in an outpatient and day-hospital setting. He is currently in charge of managing the University Radiology Unit.
CURRENT POSITION Full Professor, scientific-disciplinary sector MEDS 22/A (formerly MED36) Diagnostic Imaging and Radiotherapy. Affiliation with the Department of Translational Medicine and for Romagna, University of Ferrara.
ACADEMIC QUALIFICATIONS
1982: Degree in Medicine and Surgery, University of Pisa
1985: Diploma of Specialization in Nuclear Medicine, University of Pisa
1990: Diploma of Specialization in Radiodiagnostics, University of Ferrara
1997: Diploma of Specialization in Cardiology, University of Ferrara
TEACHING ACTIVITIES
Lecturer in Diagnostic Imaging and Radiation Protection in the following Degree Programs at UNIFE:
Medicine and Surgery
Dentistry and Dental Prosthetics
Radiology Medical Technicians
Health Professions in Diagnostic Techniques.
MANAGERIAL ACTIVITIES
Currently Director of the Department of Radiology and Laboratory Medicine of the University Hospital S. Anna in Ferrara, and the University Radiology Unit of the same Hospital.
Responsible for the University’s Radiation Protection Medical Surveillance.
Previous Positions held at the University of Ferrara:
Dean of the Faculty of Medicine, Pharmacy, and Prevention
President of the University Ethics Committee
Coordinator of the Study Program in Health Techniques in Radiology and Radiotherapy
Coordinator of the Study Program in Health Professions in Diagnostic Techniques
Director of the School of Specialization in Radiodiagnostics
Director of the School of Specialization in Nuclear Medicine
Director of the 2nd Level Master’s Program in "Science and Technology of Radiopharmaceuticals"
RESEARCH ACTIVITIES Pre-clinical research in the field of radiopharmacy aimed at designing, synthesizing, and biologically evaluating new radiopharmaceuticals for diagnostic imaging (Tc-99m) and radiometabolic therapy (Re-188).
Collaborations include:
CIS bio international (Gif-sur-Yvette, France) and the French Atomic Energy Commission (CEA): Designing in vitro and in vivo biological activity evaluation studies. This research led to the discovery of a new diagnostic agent for myocardial perfusion imaging (99mTcN-NOET).
Nihon Medi-Physics (Tokyo, Japan): Evaluating the structure-activity relationship of new diagnostic tracers with selective myocardial cell affinity. One of these compounds (99mTcN-DBODC) underwent preliminary clinical evaluation.
Schering AG (Berlin, Germany): Development of an innovative method for synthesizing new radiotherapeutic agents containing the β-emitting radionuclide rhenium-188. The product 188ReN-Lipiodol was tested clinically for hepatocellular carcinoma treatment in collaboration with Fremantle Hospital, University of Western Australia.
Development of innovative automatic synthesis modules for beta-emitting radionuclides in collaboration with industry.
Department of Physics, University of Ferrara: Development of a "YAP(S)PET" scanner, which combines CT-SPECT and CT-PET imaging for small animal research.
Collaboration with the International Atomic Energy Agency (IAEA) on Coordinated Research Projects related to Tc-99m radiopharmaceuticals for sentinel node detection and cancer diagnosis, and development of Re-188 and Y-90-based radiopharmaceuticals for radionuclide therapy.
Collaboration with INFN (National Institute of Nuclear Physics) for new methodologies for Tc-99m production via cyclotron.
Director of the section managing the "Nuclear Medicine and Molecular Imaging Laboratory" excellence center for radiochemistry under the Italian Association of Nuclear Medicine (AIMN).
Clinical research focused on nuclear medicine, specifically:
Cardiology: In collaboration with the Nuclear Medicine Unit of the University Hospital of Ferrara, evaluation of the biodistribution, dosimetry, and safety profile of the new radiopharmaceutical 99mTc-N-DBODC for myocardial perfusion imaging.
Oncology: In collaboration with Dr. R. Galeotti from the Radiology Department, preliminary assessment of the toxicity and therapeutic efficacy of 188ReN-Lipiodol for hepatocellular carcinoma treatment, administered through intra-arterial or superselective hepatic artery injection.
Radiology: Research on the appropriateness of diagnostic imaging, a crucial topic for scientific societies, HTA organizations, and clinical government authorities, focusing on the optimization of resources, cost reduction, and minimizing biological risks for patients.
CLINICAL ACTIVITIES Professor Giganti’s clinical activities currently take place at the University Radiology Unit of the S. Anna University Hospital of Ferrara, where he is responsible for the organizational and managerial aspects of the complex structure, as well as performing and reporting on around 200 exams weekly in traditional radiology (thoracic radiology) and MRI (abdomen and pelvis). Until December 2011, his clinical activity was carried out at the Nuclear Medicine Unit of the University Hospital of Ferrara. This hospital unit has a traditional gamma camera, a gamma camera with a dedicated CT scanner for attenuation correction, and mobile units for PET-CT exams. Additionally, radiometabolic therapies for hyperthyroidism and bone pain treatment using beta-emitting radionuclides were performed in an outpatient and day-hospital setting. He is currently in charge of managing the University Radiology Unit.
